Logo image of MDWD

MEDIWOUND LTD (MDWD) Stock Price, Quote, News and Overview

NASDAQ:MDWD - Nasdaq - IL0011316309 - Common Stock - Currency: USD

18.1  -0.47 (-2.53%)

After market: 18.1 0 (0%)

MDWD Quote, Performance and Key Statistics

MEDIWOUND LTD

NASDAQ:MDWD (8/15/2025, 8:00:01 PM)

After market: 18.1 0 (0%)

18.1

-0.47 (-2.53%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High22.51
52 Week Low14.14
Market Cap195.66M
Shares10.81M
Float7.99M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-24 2025-11-24
IPO03-20 2014-03-20


MDWD short term performance overview.The bars show the price performance of MDWD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

MDWD long term performance overview.The bars show the price performance of MDWD in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80 100

The current stock price of MDWD is 18.1 USD. In the past month the price decreased by -11.53%. In the past year, price decreased by -6.07%.

MEDIWOUND LTD / MDWD Daily stock chart

MDWD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 43.42 664.58B
JNJ JOHNSON & JOHNSON 17.66 425.41B
AZN ASTRAZENECA PLC-SPONS ADR 17.83 245.46B
NVS NOVARTIS AG-SPONSORED ADR 14.04 240.45B
NVO NOVO-NORDISK A/S-SPONS ADR 13.4 232.88B
MRK MERCK & CO. INC. 10.94 211.45B
PFE PFIZER INC 7.42 142.93B
SNY SANOFI-ADR 11.21 121.39B
BMY BRISTOL-MYERS SQUIBB CO 7.2 98.58B
GSK GSK PLC-SPON ADR 8.61 79.42B
ZTS ZOETIS INC 24.78 68.61B
TAK TAKEDA PHARMACEUTIC-SP ADR 50 47.37B

About MDWD

Company Profile

MDWD logo image MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. ; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.

Company Info

MEDIWOUND LTD

42 Hayarkon Street

YAVNE 8122745 IL

CEO: Sharon Malka

Employees: 111

MDWD Company Website

MDWD Investor Relations

Phone: 972779714100

MEDIWOUND LTD / MDWD FAQ

What is the stock price of MEDIWOUND LTD today?

The current stock price of MDWD is 18.1 USD. The price decreased by -2.53% in the last trading session.


What is the ticker symbol for MEDIWOUND LTD stock?

The exchange symbol of MEDIWOUND LTD is MDWD and it is listed on the Nasdaq exchange.


On which exchange is MDWD stock listed?

MDWD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MEDIWOUND LTD stock?

12 analysts have analysed MDWD and the average price target is 31.28 USD. This implies a price increase of 72.82% is expected in the next year compared to the current price of 18.1. Check the MEDIWOUND LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MEDIWOUND LTD worth?

MEDIWOUND LTD (MDWD) has a market capitalization of 195.66M USD. This makes MDWD a Micro Cap stock.


How many employees does MEDIWOUND LTD have?

MEDIWOUND LTD (MDWD) currently has 111 employees.


What are the support and resistance levels for MEDIWOUND LTD (MDWD) stock?

MEDIWOUND LTD (MDWD) has a support level at 18.09 and a resistance level at 18.25. Check the full technical report for a detailed analysis of MDWD support and resistance levels.


Is MEDIWOUND LTD (MDWD) expected to grow?

The Revenue of MEDIWOUND LTD (MDWD) is expected to grow by 18.74% in the next year. Check the estimates tab for more information on the MDWD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MEDIWOUND LTD (MDWD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MEDIWOUND LTD (MDWD) stock pay dividends?

MDWD does not pay a dividend.


When does MEDIWOUND LTD (MDWD) report earnings?

MEDIWOUND LTD (MDWD) will report earnings on 2025-11-24.


What is the Price/Earnings (PE) ratio of MEDIWOUND LTD (MDWD)?

MEDIWOUND LTD (MDWD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.64).


What is the Short Interest ratio of MEDIWOUND LTD (MDWD) stock?

The outstanding short interest for MEDIWOUND LTD (MDWD) is 10.46% of its float. Check the ownership tab for more information on the MDWD short interest.


MDWD Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MDWD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MDWD. MDWD has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MDWD Financial Highlights

Over the last trailing twelve months MDWD reported a non-GAAP Earnings per Share(EPS) of -2.64. The EPS decreased by -22.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.36%
ROE -67.58%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-80.88%
Sales Q2Q%12.78%
EPS 1Y (TTM)-22.22%
Revenue 1Y (TTM)8.22%

MDWD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to MDWD. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 30.62% and a revenue growth 18.74% for MDWD


Ownership
Inst Owners35.7%
Ins Owners1.68%
Short Float %10.46%
Short Ratio13.57
Analysts
Analysts83.33
Price Target31.28 (72.82%)
EPS Next Y30.62%
Revenue Next Year18.74%